Marksans Pharma strengthens European presence with €7.5 million QliniQ acquisition - CNBC TV18
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Stereotaxis has acquired Robocath, a medical devices business in France. Robocath designs and develops robotic-assisted catheter navigation systems used in interventional cardiology and electrophysiology procedures, supporting precise placement during complex treatments. Stereotaxis acquisitions in healthcare M&A aim to expand its portfolio of image-guided and robotic solutions for hospitals and clinics, strengthening adoption of advanced cardiac intervention technologies. The strategic acquisition was announced as a definitive agreement, with deal size undisclosed, and is expected to close subject to customary conditions.
Source
Read full article on manilatimes.netvia GN - entered into definitive agreement · April 15, 2026
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Marksans Pharma→QliniQ
Jun 1, 2026
Frazier Healthcare Partners→Altruix
May 31, 2026
Signos
May 31, 2026
Sterling Bay→Pacific Center
May 29, 2026